Vanguard Group’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $716K | Sell |
299,556
-519,683
| -63% | -$1.28M | ﹤0.01% | 3856 |
|
|
2025
Q3 | $2.18M | Sell |
819,239
-126,166
| -13% | -$374K | ﹤0.01% | 3554 |
|
|
2025
Q2 | $2.81M | Sell |
945,405
-117,367
| -11% | -$341K | ﹤0.01% | 3408 |
|
|
2025
Q1 | $3.44M | Sell |
1,062,772
-1,832
| -0.2% | -$6.32K | ﹤0.01% | 3306 |
|
|
2024
Q4 | $4.21M | Buy |
1,064,604
+2,625
| +0.2% | +$17.9K | ﹤0.01% | 3335 |
|
|
2024
Q3 | $8.21M | Buy |
1,061,979
+25,010
| +2% | +$164K | ﹤0.01% | 3061 |
|
|
2024
Q2 | $5.33M | Buy |
1,036,969
+141,654
| +16% | +$1.09M | ﹤0.01% | 3231 |
|
|
2024
Q1 | $7.28M | Buy |
895,315
+13,804
| +2% | +$79.1K | ﹤0.01% | 3132 |
|
|
2023
Q4 | $3.53M | Buy |
881,511
+9,068
| +1% | +$36.1K | ﹤0.01% | 3414 |
|
|
2023
Q3 | $3.59M | Hold |
872,443
| – | – | ﹤0.01% | 3384 |
|
|
2023
Q2 | $5.18M | Buy |
872,443
+17,974
| +2% | +$81.1K | ﹤0.01% | 3280 |
|
|
2023
Q1 | $2.95M | Hold |
854,469
| – | – | ﹤0.01% | 3536 |
|
|
2022
Q4 | $3M | Buy |
854,469
+352
| +0% | +$1.2K | ﹤0.01% | 3517 |
|
|
2022
Q3 | $3.09M | Sell |
854,117
-176
| -0% | -$828 | ﹤0.01% | 3573 |
|
|
2022
Q2 | $4.81M | Sell |
854,293
-74,384
| -8% | -$500K | ﹤0.01% | 3396 |
|
|
2022
Q1 | $8.02M | Sell |
928,677
-12,130
| -1% | -$122K | ﹤0.01% | 3269 |
|
|
2021
Q4 | $10.5M | Buy |
940,807
+55,825
| +6% | +$727K | ﹤0.01% | 3176 |
|
|
2021
Q3 | $11.5M | Buy |
884,982
+33,566
| +4% | +$535K | ﹤0.01% | 3159 |
|
|
2021
Q2 | $14.1M | Buy |
851,416
+107,826
| +15% | +$1.83M | ﹤0.01% | 3030 |
|
|
2021
Q1 | $12.8M | Buy |
743,590
+11,411
| +2% | +$213K | ﹤0.01% | 3021 |
|
|
2020
Q4 | $11.5M | Sell |
732,179
-5,717
| -0.8% | -$105K | ﹤0.01% | 2926 |
|
|
2020
Q3 | $14.1M | Sell |
737,896
-154,651
| -17% | -$2.67M | ﹤0.01% | 2614 |
|
|
2020
Q2 | $12.2M | Buy |
892,547
+173,378
| +24% | +$2.44M | ﹤0.01% | 2664 |
|
|
2020
Q1 | $7.64M | Sell |
719,169
-270,133
| -27% | -$4.4M | ﹤0.01% | 2744 |
|
|
2019
Q4 | $18.5M | Sell |
989,302
-101,182
| -9% | -$1.3M | ﹤0.01% | 2570 |
|
|
2019
Q3 | $11.4M | Buy |
1,090,484
+108,064
| +11% | +$880K | ﹤0.01% | 2748 |
|
|
2019
Q2 | $7.45M | Buy |
982,420
+259,660
| +36% | +$2.26M | ﹤0.01% | 3022 |
|
|
2019
Q1 | $7.96M | Buy |
722,760
+285,154
| +65% | +$2.31M | ﹤0.01% | 2946 |
|
|
2018
Q4 | $2.22M | Sell |
437,606
-396,917
| -48% | -$1.63M | ﹤0.01% | 3344 |
|
|
2018
Q3 | $2.65M | Buy |
834,523
+43,648
| +6% | +$170K | ﹤0.01% | 3438 |
|
|
2018
Q2 | $3.54M | Sell |
790,875
-29,045
| -4% | -$131K | ﹤0.01% | 3324 |
|
|
2018
Q1 | $4.39M | Buy |
819,920
+9,185
| +1% | +$42.3K | ﹤0.01% | 3204 |
|
|
2017
Q4 | $3.19M | Sell |
810,735
-239
| -0% | -$1.01K | ﹤0.01% | 3285 |
|
|
2017
Q3 | $3.54M | Buy |
810,974
+25,340
| +3% | +$120K | ﹤0.01% | 3237 |
|
|
2017
Q2 | $3.69M | Buy |
785,634
+41,458
| +6% | +$397K | ﹤0.01% | 3195 |
|
|
2017
Q1 | $12.3M | Buy |
744,176
+33,899
| +5% | +$444K | ﹤0.01% | 2672 |
|
|
2016
Q4 | $7.19M | Buy |
710,277
+22,394
| +3% | +$298K | ﹤0.01% | 2889 |
|
|
2016
Q3 | $9.26M | Buy |
687,883
+185,265
| +37% | +$2.72M | ﹤0.01% | 2726 |
|
|
2016
Q2 | $10.5M | Buy |
502,618
+105,511
| +27% | +$1.52M | ﹤0.01% | 2625 |
|
|
2016
Q1 | $3.75M | Buy |
397,107
+32,495
| +9% | +$269K | ﹤0.01% | 3111 |
|
|
2015
Q4 | $3.96M | Buy |
364,612
+112,976
| +45% | +$1.44M | ﹤0.01% | 3090 |
|
|
2015
Q3 | $3.76M | Buy |
251,636
+48,883
| +24% | +$856K | ﹤0.01% | 3098 |
|
|
2015
Q2 | $3.67M | Buy |
+202,753
| New | +$4.21M | ﹤0.01% | 3155 |
|
Other funds holding XBIT
RC
BCM
Vanguard Group's XBIT Position: Q4 2025 in Review
Vanguard Group reduced its XBiotech (XBIT) stake by 63% in Q4 2025, selling an estimated $1.28M and leaving 299,556 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #3856.
Vanguard Group first reported a position in XBIT in Q2 2015 and has held it in 43 quarters since. The position peaked at $18.5M in Q4 2019. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2025.
- Vanguard Group held 299,556 shares of XBiotech worth $716K as of Q4 2025.
- Vanguard Group sold 519,683 XBiotech shares in Q4 2025, an estimated $1.28M.
- XBiotech made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3856 holding.
- Vanguard Group first reported a position in XBiotech in Q2 2015 and has held it in 43 quarters since.
- Vanguard Group's XBiotech position peaked at $18.5M in Q4 2019.
- 41 funds tracked by Wall St. Rank held XBiotech as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.